Safety and Efficacy of DOACs in Patients with Advanced and End-Stage Renal Disease

Overview

Journal Int J Environ Res Public Health

Publisher MDPI

Specialties Environmental Health
Public Health

Date 2022 Feb 15

PMID 35162472

Authors

Sylwester Rogula

Aleksandra Gasecka

Tomasz Mazurek

Eliano Pio Navarese

Lukasz Szarpak

Krzysztof J Filipiak

Affiliations

Soon will be listed here.

Abstract

The prevalence of chronic kidney disease (CKD) is increasing due to the aging of the population and multiplication of risk factors, such as hypertension, arteriosclerosis and obesity. Impaired renal function increases both the risk of bleeding and thrombosis. There are two groups of orally administered drugs to prevent thromboembolic events in patients with CKD who require anticoagulation: vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs). Although VKAs remain the first-line treatment in patients with advanced CKD, treatment with VKAs is challenging due to difficulties in maintaining the appropriate anticoagulation level, tendency to accelerate vascular calcification and faster progression of CKD in patients treated with VKAs. On the other hand, the pleiotropic effect of DOACs, including vascular protection and anti-inflammatory properties along with comparable efficacy and safety of treatment with DOACs, compared to VKAs observed in preliminary reports encourages the use of DOACs in patients with CKD. This review summarizes the available data on the efficacy and safety of DOACs in patients with CKD and provides recommendations regarding the choice of the optimal drug and dosage depending on the CKD stage.

Citing Articles

Balancing the risks: continuous vs. interrupted anticoagulation during TAVI - what does the evidence say?.

Patel R, Kokori E, Olatunji G, Abraham I, Akinboade A, Agyemang E Thromb J. 2025; 23(1):7.

PMID: 39849548 PMC: 11756126. DOI: 10.1186/s12959-025-00686-z.

Fracture in Association with Anticoagulant Therapy in Patients with CKD and Atrial Fibrillation.

Khan N, Kim S, Lee S, Bykov K, Paik J Clin J Am Soc Nephrol. 2024; 20(1):31-38.

PMID: 39665574 PMC: 11737451. DOI: 10.2215/CJN.0000000578.

Efficacy and safety of novel anticoagulant therapies in patients with chronic kidney disease-a systematic review and meta-analysis.

Calderon Martinez E, Sanchez Cruz C, Diarte Acosta E, Aguirre Cano D, Espinosa A, Othon Martinez D J Nephrol. 2024; 38(1):111-126.

PMID: 39614034 PMC: 11903568. DOI: 10.1007/s40620-024-02130-3.

A comprehensive insight from molecular docking and dynamics with clinical investigation on the impact of direct oral anticoagulants on atheroprotective protein in atrial fibrillation.

Sudhan M, Janakiraman V, Ahmad S, Attia S, Subramanian R, Devi D BMC Pharmacol Toxicol. 2024; 25(1):56.

PMID: 39175081 PMC: 11342603. DOI: 10.1186/s40360-024-00785-z.

Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in low-weight patients with atrial fibrillation.

Chen K, Hsu Y, Chou C, Hsu C, Chang S, Yu W J Thromb Thrombolysis. 2024; 57(7):1268-1280.

PMID: 39143401 PMC: 11496318. DOI: 10.1007/s11239-024-03016-8.

References

Mezzano D, Pais E, Aranda E, Panes O, Downey P, Ortiz M . Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int. 2001; 60(5):1844-50. DOI: 10.1046/j.1523-1755.2001.00996.x. View

January C, Samuel Wann L, Calkins H, Chen L, Cigarroa J, Cleveland Jr J . 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the.... J Am Coll Cardiol. 2019; 74(1):104-132. DOI: 10.1016/j.jacc.2019.01.011. View

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B . 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016; 50(5):e1-e88. DOI: 10.1093/ejcts/ezw313. View

Ellinghaus P, Perzborn E, Hauenschild P, Gerdes C, Heitmeier S, Visser M . Expression of pro-inflammatory genes in human endothelial cells: Comparison of rivaroxaban and dabigatran. Thromb Res. 2016; 142:44-51. DOI: 10.1016/j.thromres.2016.04.008. View

Eikelboom J, Connolly S, Brueckmann M, Granger C, Kappetein A, Mack M . Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013; 369(13):1206-14. DOI: 10.1056/NEJMoa1300615. View

Hart R, Eikelboom J, Ingram A, Herzog C . Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nat Rev Nephrol. 2012; 8(10):569-78. DOI: 10.1038/nrneph.2012.160. View

Bleyer A, Shemanski L, Burke G, Hansen K, Appel R . Tobacco, hypertension, and vascular disease: risk factors for renal functional decline in an older population. Kidney Int. 2000; 57(5):2072-9. DOI: 10.1046/j.1523-1755.2000.00056.x. View

Mabley J, Patel J, Sayed A, Arya R, Scutt G . Direct oral anticoagulant (DOAC)-mediated vasodilation: Role of nitric oxide. Thromb Res. 2019; 176:36-38. DOI: 10.1016/j.thromres.2019.02.014. View

Koretsune Y, Yamashita T, Kimura T, Fukuzawa M, Abe K, Yasaka M . Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment. Circ J. 2015; 79(7):1486-95. DOI: 10.1253/circj.CJ-14-0942. View

10.

Brandenburg V, Schurgers L, Kaesler N, Pusche K, van Gorp R, Leftheriotis G . Prevention of vasculopathy by vitamin K supplementation: can we turn fiction into fact?. Atherosclerosis. 2015; 240(1):10-6. DOI: 10.1016/j.atherosclerosis.2015.02.040. View

11.

Aursulesei V, Costache I . Anticoagulation in chronic kidney disease: from guidelines to clinical practice. Clin Cardiol. 2019; 42(8):774-782. PMC: 6671778. DOI: 10.1002/clc.23196. View

12.

Lee S, Choi E, Park C, Han K, Jung J, Oh S . Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Low Body Weight. J Am Coll Cardiol. 2019; 73(8):919-931. DOI: 10.1016/j.jacc.2018.11.051. View

13.

Fox C, Larson M, Leip E, Culleton B, Wilson P, Levy D . Predictors of new-onset kidney disease in a community-based population. JAMA. 2004; 291(7):844-50. DOI: 10.1001/jama.291.7.844. View

14.

Chan K, Giugliano R, Patel M, Abramson S, Jardine M, Zhao S . Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. J Am Coll Cardiol. 2016; 67(24):2888-99. DOI: 10.1016/j.jacc.2016.02.082. View

15.

Wang X, Tirucherai G, Marbury T, Wang J, Chang M, Zhang D . Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2015; 56(5):628-36. DOI: 10.1002/jcph.628. View

16.

Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T . Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2006; 71(2):159-66. DOI: 10.1038/sj.ki.5002017. View

17.

Bangalore S, Maron D, OBrien S, Fleg J, Kretov E, Briguori C . Management of Coronary Disease in Patients with Advanced Kidney Disease. N Engl J Med. 2020; 382(17):1608-1618. PMC: 7274537. DOI: 10.1056/NEJMoa1915925. View

18.

Martin K, Beyer-Westendorf J, Davidson B, Huisman M, Sandset P, Moll S . Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016; 14(6):1308-13. PMC: 4936273. DOI: 10.1111/jth.13323. View

19.

Schurgers L, Joosen I, Laufer E, Chatrou M, Herfs M, Winkens M . Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype. PLoS One. 2012; 7(8):e43229. PMC: 3430691. DOI: 10.1371/journal.pone.0043229. View

20.

Marinigh R, Lane D, Lip G . Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol. 2011; 57(12):1339-48. DOI: 10.1016/j.jacc.2010.12.013. View